Riabni (rituximab)

pCPA File Number: 21362
Negotiation Status:
Active Negotiation
Indication(s):
Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Rheumatoid Arthritis (RA), Granulomatosis with Polyangitis (GPA), Microscopic Polyangitis (MPA)
Sponsor/Manufacturer:
Amgen Canada Inc.
CADTH Project Number:
Not Applicable
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable